<DOC>
	<DOCNO>NCT02183428</DOCNO>
	<brief_summary>The objective study investigate effect multiple dos BI 1356 give daily estimate high therapeutic dose 5 mg steady state pharmacokinetics , safety , tolerability single oral conventional therapeutic dose 1.75 mg glyburide . In addition , effect glyburide single oral dose 1.75 mg conventional therapeutic dose multiple dose pharmacokinetics BI 1356 investigate . Pharmacokinetic profile glyburide determine give alone combination BI 1356 . Pharmacokinetic profile BI 1356 inactive metabolite CD 1750 determine steady state BI 1356 give alone combination glyburide .</brief_summary>
	<brief_title>Bioavailability BI 1356 Glyburide Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Glyburide</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Healthy female male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead ( ECG ) Electrocardiogram , clinical laboratory test Age ≥18 Age ≤55 year BMI ≥18.5 BMI ≤29.9 kg/m2 ( Body Mass Index ) Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial , include herbal product Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalaemia , family history Long QT Syndrome ) Galactose intolerance Lactase deficiency Glucosegalactosemalabsorption For female subject : Pregnancy plan become pregnant within 2 month study completion Positive pregnancy test No adequate contraception e.g . , sterilisation , IUD ( intrauterine device ) , use barrier method contraception least 3 month prior participation study Not willing unable use reliable method barrier contraception ( diaphragm spermicidal cream/jelly condoms spermicidal foam ) , 2 month completion/termination trial Partner unwilling use condom Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>